Evidence map›Paper›PMID 31512057›Full record

ArticlePathology oncology research : POR2020

Monoclonal Caveolin 1 Expression in the Differential Diagnosis of Malignant Pleural Mesothelioma and Pulmonary Adenocarcinoma: Is it Useful?

Zehra Bozdag, Ediz Tutar, Omer Faruk Dizibuyuk, Kemal Bakir

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Pathology oncology research : POR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Zehra BozdagDepartment of Pathology, Gaziantep University, Medical School, Gaziantep, Turkey. zbozdagmd@gmail.com.
Ediz TutarDepartment of Pathology, Gaziantep University, Medical School, Gaziantep, Turkey.
Omer Faruk DizibuyukDepartment of Pathology, Gaziantep University, Medical School, Gaziantep, Turkey.
Kemal BakirDepartment of Pathology, Gaziantep University, Medical School, Gaziantep, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study we aim to demonstrate the value of monoclonal Caveolin 1 expression in distinguishing between malignant pleural mesothelioma and pulmonary adenocarcinoma. Total of 129 cases, consisting of 68 cases of malignant pleural mesothelioma (51 epitheloid, 12 biphasic, and 5 sarcomatoid type) and 61 cases of pulmonary adenocarcinoma were examined and stained with monoclonal Caveolin-1. Caveolin 1 expression with a membranous and /or cytoplasmic pattern was detected only in 32.35% (n:22/68) of malignant pleural mesothelioma and 6.5% (n:4/61) of pulmonary adenocarcinoma cases. This finding suggests that the choice of poly/monoclonal antibody for Caveolin 1 in the differential diagnosis of malignant pleural mesothelioma and pulmonary adenocarcinoma is important.

Indexed as

Adenocarcinoma of LungAgedAntibodies, MonoclonalBiomarkers, TumorCaveolin 1Diagnosis, DifferentialFemaleHumansImmunohistochemistryLung NeoplasmsMaleMesothelioma, MalignantMiddle AgedPleural NeoplasmsAntibodies, MonoclonalBiomarkers, TumorCAV1 protein, humanCaveolin 1Caveolin 1MesotheliomaPulmonary adenocarcinoma

Identifiers

PMID31512057

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.